1 / 57

Polymyalgia Rheumatica and Giant Cell Arteritis

Polymyalgia Rheumatica and Giant Cell Arteritis. History of PMR and GCA. First description: 940-1010 BC Treatment was removal of affected artery English literature Bruce (1888) PMR – “senile rheumatic gout” Hutchinson (1890) – provided description of GCA Horton (1932)

conner
Download Presentation

Polymyalgia Rheumatica and Giant Cell Arteritis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Polymyalgia Rheumatica and Giant Cell Arteritis

  2. History of PMR and GCA • First description: 940-1010 BC • Treatment was removal of affected artery • English literature • Bruce (1888) PMR – “senile rheumatic gout” • Hutchinson (1890) – provided description of GCA • Horton (1932) • Classic histology findings • Coined “giant cell arteritis” • Barber (1957) • Coined “polymyalgia rheumatica”

  3. Pathogenesis • Genetic predisposition influenced by exposures • Increased incidence @ higher latitudes • Scandinavian background • Occasional familial cases • Initiating viral pathogen? • Parainfluenza virus type1 • Mycoplasma • Parvovirus

  4. Genetics of PMR and GCA • HLA-DRB1*01 and *04 • Associated w/ susceptibility to GCA/PMR • Rheumatoid Arthritis • Mutually exclusive populations • Different part of genes involved in each condition

  5. Common Pathogenesis of PMR and GCA • Activated circulating monocytes • Inflammatory cytokine production • Th1 response in vessel wall • No autoantibody component NEJM 2003;349(2): 160-169.

  6. Pathogenesis of GCA • A: Activation of Dendritic cells • B: Oxidative damage by macrophages • C, D: Differential expression of VEGF and PDGF NEJM 2003;349: 160-169.

  7. Relation of PMR to GCA • PMR seen in 40-50% of pts w/ GCA • About 15% of PMR pts develop GCA • Some view PMR as forme fruste GCA • Vasculitis remains subclinical

  8. Epidemiology of PMR • Prevalence: 3300 per 100,000 • Incidence • Scandinavian/N. European: 50-68/100,000 • Spain, Italy: 12-18 per 100,000 • Women > Men, about 3:1 • Highly unlikely in those < age 50 • Mean age at onset is 70 Gonzalez-Gay et al. Arthritis Rheum 2009;61:1454-1461

  9. Polymyalgia Rheumatica (PMR) • Clinical syndrome • Seen in “elderly” patients • Characterized by pain/stiffness (> 4 wks) • Involves neck, shoulder initially then hip region • Constitutional symptoms common • Laboratory evidence of systemic inflammation • ESR, CRP, anemia

  10. Other PMR Features • Fever/chills • GCA, infection, malignancy • Arthritis / joint inflammation • Non-erosive synovitis

  11. Arthritis in PMR NEJM 2002; 347, 261-278.

  12. Diagnosis of PMR • Compatible clinical syndrome • Exclusion of diff dx • Elevated acute phase response • Response to corticosteroids NEJM 2002; 347:261-278.

  13. Differential Diagnosis - PMR RS3PE – Remitting Symmetric Synovitis with Pitting Edema

  14. PMR and Malignancy • No excess malignancy in PMR • Consider paraneoplastic PMR-like syndrome • Poor or incomplete response to steroids • Young age • Relatively low ESR • Most common malignancies • Colon, Lung, Kidney, Leukemia, Lymphoma • Without findings suggestive of cancer ensure age-appropriate screening is current

  15. Treatment of PMR: Steroids • Very responsive to oral steroids: 10 – 20 mg daily • What is best initial dose? • Ann Rheum Dis 1989;48:658-661. • Average duration of steroid therapy 2 years • Prevention of bone loss • Gradually taper steroids • Some patients require low dose prednisone • ? Role of steroid sparing agents • Monitor for relapses • Clinical features > labs

  16. Sample Steroid Taper for PMR • Start 20 mg daily for 4 weeks • Decrease by 2.5 mg daily every 2-4 weeks to 10 mg daily • From 10 mg daily decrease by 1 mg daily every 2-4 weeks • For relapse return to higher dose

  17. Methotrexate for PMR • Limitations of trials • Few patients • Varying steroid and methotrexate doses • Short duration • Prior negative studies • Feinberg et al. J Rheum 1996;23(9):1550-1552. • Open-controlled; 12.5mg/wk not steroid sparing • Van der Veen et al. Annals Rheum Dis 1996;55:218-223. • RDBPC; 7.5 mg/week not steroid sparing

  18. Methotrexate for PMR • Two positive trials • Ferraccioli et al.J Rheum 1996 ;23(4):624-628. • Open, randomized; 10 mg methotrexate IM weekly • Total steroid dose reduced at 1 year • Caporali et al. Ann Intern Med 2004;141:493-500. • RDBPC; 10 mg methotrexate po weekly; 72 patients • 25 mg prednisone both arms • Shorter prednisone treatment / lower dose in MTX arm • High starting dose prednisone (25 mg daily) • High weekly folinic acid supplement (7.5 mg weekly)

  19. Other “Steroid Sparing” Drugs in PMR • Azathioprine • De Silva et al. Ann Rheum Dis 1986 Feb;45(2):136-138. • 31 patients, 100-150 mg / day azathioprine • Steroid sparing effect seen at 1 year • Anti-TNF • Enbrel: Catanoso et al.Arthritis Rheum. 2007 Dec 15;57(8):1514-9. • Open case series 6 patients, steroid dependent PMR • 24 weeks treatment, 36 weeks follow-up • Significant reduction in steroid dose • Infliximab: Salvarani et al. J Rheumatol. 2003 Apr;30(4):760-3. • 3 of 4 patients had clinical response sustained at 1 year

  20. Epidemiology - GCA • Age >50 years (mean 70) • Incidence increases progressively w/ age • Most common vasculitis in northen hemisphere • Gender • Women > men about 2:1 • Population prevalence (Age 50 or older) • Scandinavian/N. European: 22-76/100K • Spain, Israel: 10 per 100K • France, Italy: 6.9-9.4 per 100K • Shelby Co, TN: 2.2 Cauc., 0.4 AA per 100K

  21. Synonyms of GCA • Temporal arteritis • Cranial arteritis • Granulomatous arteritis • Horton’s headache

  22. GCA: Classification Criteria NEJM 2002; 347, 261-278.

  23. Presentations of GCA • Cranial Arteritis • Headaches • Ischemic Optic Neuropathy • Jaw Claudication • PMR • Fever/Wasting Syndrome • Fever and chills • Anorexia, weight loss • Night sweats • Weakness • Depression GCA PMR Syndrome • Large-vessel GCA/aortitis • Arm claudication • Pulselessness • Raynaud’s phenomenon • Aortic aneurysm • Aortic insufficiency • PMR • Isolated PMR • Pelvic girdle muscles • Pain in shoulder and • Stiffness

  24. Cranial Arteritis - Symptoms • Headache – 2/3 of patients • Throbbing, sharp or dull • Usually severe, seek medical attention • Scalp tenderness • Usually over temporal artery • Wearing glasses, grooming, lying down • Jaw/tongue claudication – up to 50% of patients • Masseter/temporalis muscles • Painful dysphagia

  25. Eye symptoms in GCA • Various presentations • Diplopia • Amaurosis fugax • Scotoma • Ptosis • Partial or complete blindness • Above can be transient or permanent • Permanent partial/complete blindness • 15 to 20% of patients in most literature

  26. GCA – Other Symptoms • Musculoskeletal complaints are common • PMR (40%) • Peripheral arthritis • Swelling and pitting edema • Arm claudication • 10-25% patients • Bruits • Diminished neck or arm pulses

  27. GCA – Other Symptoms • CNS events – 20 to 30% of patients • TIA or CVA • Carotid/vertebrobasilar • Neuropathy • Pulmonary – up to 25% • Cough, hoarseness, chest pain • Pulmonary hemorrhage (case report)

  28. GCA as an FUO • Subset of patients with: • Systemic inflammatory syndrome • Malaise, anorexia, weakness • Fatigue, wasting, depression • Physical exam not consistent with: • Cranial arteritis • Large vessel occlusive disease • PMR

  29. Large-vessel GCA • 10-15% of patients • Targets aortic branches • Carotid, subclavian, axillary arteries • Aortic arch syndrome • Claudication of arms • Absent/asymmetrical pulses • Parasthesias, Raynaud’s phenomenon • Occasional peripheral gangrene

  30. Large-vessel GCA • Often without cranial arteritis • No headaches, other cranial symptoms • Normal temporal artery exam • 50% of temporal artery biopsies negative

  31. Giant Cell Arteritis - Exam

  32. Temporal Arteries • Thickened, tender and nodular • Occasionally erythematous • Pulses reduced or absent • 1/3 of patients, temporal arteries grossly normal • Other external carotid branches • Occipital/superficial scalp vessels

  33. Cranial arteritis and the eye • Ophthalmologic emergency • Prompt treatment can prevent blindness • Ischemic optic neuropathy • Most common cause of visual loss

  34. Causes of visual loss in GCA % of 63 Patients AION – anterior ischemic optic neuropathy BRAO – branch retinal artery occlusion PION – posterior ischemic optic neuropathy CI – choroidal infarct CRAO – central retinal artery occlusion OA – optic atrophy (unclear etiology) Liu et al. Ophthalmology 1994;101:1779-1785.

  35. Other Exam Findings • Vascular bruits • Carotid, Subclavian, Axillary • Differential BP between arms • Diminished pulses

  36. Laboratory Features of GCA • Elevated ESR, CRP • Up to 23% with normal ESR at diagnosis • Elevated IL-6 • Highest sensitivity for ongoing disease • Both before/after corticosteroid therapy • Anemia of chronic disease • Elevated platelet count • Elevated alkaline phosphatase

  37. Differential Diagnosis – GCA • Other vasculitis or pseudovasculitis • Vascular headache/migraine • Infections (acute sinusitis) • Hypothyroidism • Neoplastic / paraneoplastic process • Multiple myeloma, leukemia, lymphoma • Joint disease (OA, RA) • PM/DM, other myositis

  38. Making the Diagnosis of GCA • Compatible clinical syndrome • Exclusion of differential diagnosis • Look for physical exam clues • Majority have dramatic acute phase response • Superficial temporal artery • Easiest site to biopsy • Most useful for intermediate pre-test probability • False negative biopsies can occur: • Take a sufficient length of biopsy (5 cm) • Examine serial sections • Consider contralateral bx if 1st is negative • Limit time of treatment prior to biospy

  39. Utility of Signs and Symptoms in Suspected Giant-Cell Arteritis Weyand, C. M. et. al. Ann Intern Med 2003;139:505-515.

  40. Timing of Temporal Artery Biopsy • Ray-Chaudhuri et al.Br J Ophth 2002; 86: 530-532. • Prospective study of 11 patients • All met ACR criteria for GCA (before bx) • All started on steroids at time of dx • 9/11 - Positive biopsies overall • 6/7 - Biopsy (+) 4-6 wks after steroids • Narvaez et al.Semin Arthritis Rheum. 2007 Aug;37(1):13-9. • 35/45 biopsies (+) within 2 weeks • 13/20 biopsies (+) 2-4 weeks • 2/5 biopsies (+) 4 weeks or more

  41. Histopathology • 50% have pan-arteritis with giant cell formation, often in close proximity to disrupted elastic lamina • Large and medium arteries • Involvement is focal and segmental

  42. Giant-Cell Arteritis of the Temporal Artery Weyand C and Goronzy J. N Engl J Med 2003;349:160-169

  43. Adjunctive Diagnostic Tools • Ultrasound • “Dark halo” around temporal artery • Results of 86 patients (U/S then bx) • Any halo, 40% sens and 79% spec • 1mm or >, 40% sens and 93% spec • Conclusion • Only modest predictor of positive biopsy • Did not improve dx accuracy of PE Salvarani et al. Annals 2002;137: 232-238.

  44. Ultrasound - Halo

  45. Other Diagnostic Tools If extracranial GCA suspected, may consider: • Angiography • Document disease of large arteries • MRA • Useful for diagnosis • Rheumatology (Oxford). 2005 Apr;44(4):479-83. • May improve finding of vasculitis in FUO • Annals Rheum Dis. 2005 Jan;64(1):105-10 .

  46. Large Vessel GCA • Tapering of L maxillary artery • Aneurysm of ascending aorta • Dilation and thickening of descending aorta

  47. PET Scan and GCA • Vascular FDG uptake at diagnosis • 29 of 35 patients (83%) • Most common in subclavian vessels (74%) • Aorta 51% thoracic and 54% abdominal • Not predictive of relapse Blockmans et al. Arthritis Rheum 2006;55(1):131-137.

  48. GCA Treatment • Corticosteroids • Initiate promptly to avoid visual loss • Start with 40-60 mg/day of prednisone (1mg/kg) • Single or divided doses • Recent visual loss • Hospitalize for IV methylprednisolone • Pulse dose qday or divided q6h • Aspirin reduces stroke • 2 retrospective studies (341 patients total) • Arthritis Rheum. 2004 Apr;50(4):1332-7. NNT = 5. • Arthritis Rheum. 2006 Oct;54(10):3306-9. NNT = 3.

More Related